NL-OMON51194已完成2 期
IBIS: A single-centre, phase II study to evaluate the safety, tolerability and pharmacokinetics of 2-IminoBiotin in acute Ischemic Stroke due to large vessel occlusion - IBIS: 2-iminobiotin for ischemic stroke
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Adults (age > 18 years for males and age >49 years for females)
- •A clinical diagnosis of AIS
- •Disabling stroke defined as a baseline NIH stroke scale score =/>5
- •Alberta Stroke Program Early CT score (ASPECTS) > 4 on CT (or MRI)
- •Presence of an intracranial LVO of the anterior circulation (distal ICA, M1
- •or proximal M2 segment of the MCA) on CTA, MRA or DSA
- •Start of EVT (arterial access puncture) possible within the first 6 hours
- •after stroke onset or last seen well
- •EVT with declared first endovascular approach as either stent retriever,
- •aspiration device or a combined approach
- •Pre-stroke independent functional status in activities of daily living
排除标准
- •No informed consent
- •Contraindication to EVT or EVT > 6 hours after symptom onset (or last seen
- •Evidence of a large core of established infarction defined as ASPECTS 0-4.
- •Evidence of absence/poor collateral circulation on CTA (Tan collateral score
- •of 0 or 1)
- •Known co-morbidity with a life expectancy of <6 months prior to acute
- •ischemic stroke
- •Women aged 49 or less or known pregnancy*
- •Cognitive impairment (documented dementia) known prior to ischemic stroke
- •Pre-stroke disability which interferes with the assessment of functional
- •outcome at 90 days, i.e. mRS >2
- •Intent to use any endovascular device other than a stent retriever or clot
- •aspiration device or intra-arterial medications as the initial thrombectomy
- •History of life threatening allergy (more than rash) to contrast medium
- •Evidence of acute hemorrhage on CT, MRI
- •· Significant mass effect with midline shift.
- •· Subjects with occlusions in multiple vascular territories (e.g., bilateral
- •anterior circulation, or anterior/posterior circulation)
- •· Severe known renal impairment defined as requiring dialysis (hemo- or
- •peritoneal) or if known a eGFR < 20 mL/min.
- •*As 2-IB has not been tested yet for embryonic toxicity and limited pre- and
- •postnatal development studies have been performed, women who can be pregnant
- •must not be included be in this study.
研究者
相似试验
尚未招募
不适用
IBIS: 2-iminobiotin for ischemic strokeNL-OMON29036Haaglanden Medisch Centrum18
进行中（未招募）
1 期
IBIS: 2-iminobiotin for ischemic strokeAcute ischemic stroke due to proximal large vessel occlusionEUCTR2021-002162-40-NLHaaglanden Medisch Centrum36
进行中（未招募）
1 期
Combined treatment (hormone and biological therapy) for patients with advanced breast cancer with hormone (HR) positive and HER2 negative receptorsHR+, HER2 negative advanced breast cancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2018-002514-12-ITFONDAZIONE SANDRO PITIGLIANI PER LA LOTTA CONTRO I TUMORI - ONLUS194
进行中（未招募）
不适用
Phase II clinical trial of dinutuximab in high risk neuroblastoma.High-risk neuroblastomaMedDRA version: 16.1Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004864-69-ESFundació Sant Joan de Deu de Barcelona
已完成
2 期
The safety of Cpn10 in patients with multiple sclerosisNeurological - Multiple sclerosisMultiple SclerosisACTRN12606000037505CBio Limited50